ClinicalTrials.gg
RecruitingNCT07106151ORKID-2Updated Feb 27, 2026

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

An interventional study of Transmission of additional AKI-D recovery information and No additional AKI-D recovery information in AKI, AKI - Acute Kidney Injury and Dialysis Patients, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Acute Kidney Injury by University of California, San Francisco — 5 open to participants now, 6 under way, 1 of them phase 3. Acute Kidney Injury · University of California, San Francisco.

Planned enrollment
7th of 10
40 · median 55
Started
2026
with 2 others
No phase
5 of 11
2 open now
Registered
9th of 11
by date

Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, and was the 9th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 11 studies in Acute Kidney Injury by University of California, San Francisco are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Kidney Injury by University of California, San Francisco, or all of them as a file.
02

Study summary

Providing additional information to patients with acute kidney injury who continue dialysis after hospital discharge and to the accepting kidney doctor (nephrologist) who manages their dialysis may be feasible and beneficial. This study will pilot measuring the patient's residual kidney function at the time of discharge and communicating that result to the accepting nephrologist and the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.

03

Conditions studied

  • AKI
  • AKI - Acute Kidney Injury
  • Dialysis Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AKI-D (not ESKD, as determined by the clinical inpatient nephrology team)
  • Age ≥ 18 years
  • Planned for continued dialysis outside the acute hospital setting (at outpatient dialysis unit/SNF/LTACH, not planned transfer to another short-stay acute care hospital).

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Prisoner
  • Unable to consent and no surrogate decision maker available
  • Clinical team declines to allow approach for study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Additional AKI-D recovery information

    Behavioral: Transmission of additional AKI-D recovery information

  • Active comparator
    No additional AKI-D recovery information

    Other: No additional AKI-D recovery information

Interventions

  • BehavioralTransmission of additional AKI-D recovery information

    Measuring residual kidney function at the time of hospital discharge by timed urine collection (6-24 hours in duration), transmitting the results (urine volume, urea clearance, and creatinine clearance) to the accepting nephrologist and to the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.

  • OtherNo additional AKI-D recovery information

    The same timed urine collection will be collected at the time of hospital discharge as in the intervention arm, but in the control arm the results will not be transmitted to the accepting nephrologist or to the patient and no information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule will be transmitted. Instead, the research team will call the accepting nephrologist to alert them that this is an AKI-D patient that is being followed by the research team for recovery for up to 60 days.

06

What researchers measure

Primary outcomes

  1. Feasibility: The proportion of patients who complete the timed urine collection within seven days before discharge and are able to have the results successfully transmitted to the accepting nephrologist and patient.

    Time frame: Baseline

Secondary outcomes

  1. Recruitment rate: Number of patients enrolled per month

    Time frame: Total study duration, anticipated 2 years

  2. Screening-to-recruitment ratio: Number of patients who meet inclusion criteria divided by the number of patients enrolled.

    Time frame: Total study duration, anticipated 2 years

  3. Number of post-discharge urine collections completed

    Time frame: Study day 60

  4. Proportion prescribed a <3x/wk hemodialysis schedule at any time within 60 days of hospital discharge

    Time frame: Study day 60

  5. Proportion who recover from needing dialysis

    Time frame: Study day 60

  6. Proportion who trial a <3x/wk hemodialysis schedule but subsequently need to be increased to >= 3x/wk during the 60-day follow-up.

    Time frame: Study day 60

  7. Incidence of adverse events

    Time frame: Study day 60

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 23 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 6, 2025
StartActual
Feb 23, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07106151
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Feb 23, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Ian E McCoy, MD, MS
Contact
ian.mccoy@ucsf.edu
415-353-2507
Ian E McCoy, MD, MS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion